

1 **Prevalence Threshold and Temporal Interpretation of Screening Tests:**

2 **The Example of the SARS-CoV-2 (COVID-19) Pandemic**

3

4 Jacques Balayla MD, MPH¹

5 Ariane Lasry B.Sc¹

6 Yaron Gil MD¹

7 Alexander Volodarsky-Perel MD¹

8

9 ¹ Department of Obstetrics and Gynecology, McGill University, Montreal, Quebec,

10 Canada

11

12

13 No funding was received for this study.

14

15 The authors have no conflicts of interest to report.

16

17

18 **Word Count: 1,651**

19

20

21

22

23

24

25 **Corresponding Author**

26

27 Dr. Jacques Balayla MD, MPH, CIP, FRCSC

28 Department of Obstetrics and Gynecology

29 Jewish General Hospital

30 McGill University

31 Montreal, Canada

32 Jacques.balayla@mail.mcgill.ca

33 Abstract

34 The curvilinear relationship between a screening test's positive predictive value
 35 (PPV) and its target disease prevalence is proportional. In consequence, there is an
 36 inflection point of maximum curvature in the screening curve defined as a function of the
 37 sensitivity (a) and specificity (b) beyond which the rate of change of a test's PPV declines
 38 sharply relative to disease prevalence (ϕ). Herein, we demonstrate a mathematical model
 39 exploring this phenomenon and define the prevalence threshold point (ϕ_e) where this
 40 change occurs as:

$$\phi_e = \frac{\sqrt{a(-b+1)} + b - 1}{(a+b-1)}$$

42 Understanding where this prevalence point lies in the curve has important
 43 implications for the interpretation of test results, the administration of healthcare systems,
 44 the implementation of public health measures, and in cases of pandemics like SARS-
 45 CoV-2, the functioning of society at large. To illustrate the methods herein described, we
 46 provide the example of the screening strategies used in the SARS-CoV-2 (COVID-19)
 47 pandemic, and calculate the prevalence threshold statistic of different tests available
 48 today. This concept can help contextualize the validity of a screening test in real time,
 49 thereby enhancing our understanding of the dynamics of the current pandemic.

50

51 **Keywords:** screening curve, positive predictive value, prevalence threshold, COVID-19,

52 Bayes' Theorem

53 **Introduction**

54 The novel SARS-CoV-2 (COVID-19) has reached over 4 million confirmed cases
55 worldwide; in the United States alone, the death toll totals close to 90,000 to date [1].
56 Despite efforts to contain its spread, the number of confirmed cases has continued to rise.
57 These estimations have been largely based on polymerase chain reaction (PCR) detection
58 of actively replicating viral material, found only among individuals who are actively
59 infected at the time of testing. Those who recover from the virus without having been
60 tested during the window of viral shedding are not included in prevalence estimates;
61 neither are asymptomatic individuals, roughly approximated as 18 to 30% of those
62 infected [2, 3]. Current estimates thus understate the true prevalence of COVID-19 by
63 failing to include the aforementioned groups. Whereas accurate prevalence estimates are
64 needed to inform public health measures, screening methods that depend on actively
65 replicating viral organisms will become less reliable as recovery proceeds and the
66 resulting prevalence of active infection among the population tapers. Bayes theorem thus
67 demonstrates the point beyond which the positive predictive value (PPV) of currently
68 employed PCR screening will decline as the curve ‘flattens’ over time. In contrast,
69 serologic testing for COVID-19 antibodies persist in plasma well beyond the period of
70 active infection; as recovery from active infection increases, so too will the cumulative
71 prevalence of seropositivity among the population over time. Herein, we use differential
72 equations to assess the geometry of screening curves and aim to describe the prevalence
73 threshold point beyond which the PPV of various COVID-19 screening tests declines
74 most acutely. Though this example is specific to the COVID-19 pandemic, the methods

herein described apply to all screening tests whose sensitivity and specificity parameters are known.

Validity of Screening Tests

The validity of a screening test is defined as the ability to correctly delineate individuals who have a given disease or condition from those who do not. The following four parameters are used to assess the validity of screening tests: sensitivity a , specificity b , positive predictive value ϕ , and negative predictive value σ . Sensitivity refers to the proportion of people with a given disease who test positive for said disease, also termed the true positive rate. Specificity, also termed true negative rate, refers to the proportion of people without said disease who indeed test negative. Sensitivity and specificity are properties inherent to the screening test itself and are unaffected by the prevalence of disease in a given population. On the other hand, the positive predictive value is defined as the percentage of patients with a positive test that do in fact have the disease, and conversely, the negative predictive value refers to the percentage of patients with a negative test that do not have the disease. These two parameters are dependent upon the prevalence of disease being studied. Using Bayes' theorem, we can derive the following equation expressing positive predictive value $p(\phi)$ as a function of disease prevalence ϕ .

Equation 1. *The Screening Curve Equation*

$$\rho(\phi) = \frac{a\phi}{a\phi + (1 - b)(1 - \phi)} = \frac{a\phi}{a\phi + b\phi - b - \phi + 1}$$

where:

ϕ = prevalence, $p(\phi)$ = positive predictive value, a = sensitivity and b = specificity

96 Prevalence Threshold of a Screening Test

97 Bayes' theorem describes the probability of an event, based on prior knowledge of
 98 conditions that might be related to the event. The relationship between a screening test's
 99 positive predictive value, $p(\phi)$, and its target disease prevalence ϕ is proportional - though
 100 not linear in all but one case where the sum of sensitivity and specificity equals one.
 101 From this curvilinear relationship, as stipulated in Figure 1, we can derive the prevalence
 102 threshold ϕ_e at which the sharp inflection point in the screening curve occurs, as depicted
 103 by the following equation (derivation available as a supplement).

104 Equation 2. The Prevalence Threshold Equation

$$\phi_e = \frac{\sqrt{a(-b+1)} + b - 1}{(a + b - 1)}$$

106 where:

107 ϕ_e = prevalence threshold, a = sensitivity and b = specificity

109 Nasopharyngeal Swab RT-PCR Screening Test for COVID-19


110 The Food and Drug Administration (FDA) published the analytical sensitivity and
 111 specificity of the currently employed COVID-19 reverse transcription polymerase chain
 112 reaction (RT-PCR) test [4]. The limit of detection (LoD) for the minimum detectable
 113 concentration of SARS-CoV-2 genome (ie. sensitivity) in-vitro was set at 95%.
 114 Additionally, the COVID-19 RT-PCR was tested against 30 respiratory microorganisms,
 115 which yielded a specificity nearing 100%. While the above are *analytical* properties of
 116 the COVID-19 RT-PCR test, estimates of its *clinical* properties vary significantly

between studies – particularly since some margin of error may result from improper sampling by health care workers (wrong angle, too fast to withdraw and swab, etc.), varying viral load and the subclinical stage when screening is carried out (colonization, incubation, prodrome or acute infection). We will therefore use the FDA’s published estimates for simplicity, where ϕ_e = prevalence threshold for detection of COVID-19, a = sensitivity = 0.95, b = specificity = 0.99 and $a + b = 1.94$. Thus, as per equation 2, the prevalence threshold for RT-PCR detection of COVID-19 is calculated as follows:

Equation 3. Prevalence threshold for the COVID-19 RT-PCR screening test

$$\frac{\sqrt{.95(-.99 + 1)} + .99 - 1}{(1.94 - 1)} = .093$$

In graphic form, the screening curve depicts the PPV as a function of prevalence as such:



The vertical line in red represents the prevalence threshold ϕ_e at 0.093 (9.3%).

In clinical practice, the sensitivity and specificity of the COVID-19 RT-PCR test are likely lower than those estimated analytically by the FDA; the prevalence threshold for detection that we have estimated above is thus likely conservative. Nonetheless, the implication is such that below a prevalence of 9.3% actively replicating cases of COVID-19 in the population, the PPV of RT-PCR testing declines almost exponentially. In other words, we would expect a sharp increase in the number of false positive screening tests, in turn falsely increasing the estimated prevalence of disease. Even with a conservative estimation of the prevalence threshold, there are potentially significant health, social, and economic implications of false positive screening tests.

Serology Testing as a Public Health Tool

Serology testing for SARS-CoV-2 involves blood-based testing for antibodies to COVID-19. This screening method identifies all groups of individuals sub-acutely infected or recovered from COVID-19, including those who may be asymptomatic at the time of testing. Use of this tool can thus provide public health officials with a more reliable estimation of the spread of COVID-19 and its cumulative prevalence among different populations over time. Furthermore, this information can bring forth attempts at a better understanding of disease transmission and immunity, which regarding COVID-19, is largely uncertain up until this point.

The Johns Hopkins Center for Health Security recently released a report outlining the sensitivity and specificity of various serology tests approved for diagnostic use in the United States [5]. These are summarized in Table 1, with prevalence thresholds estimated for each test. In contrast to RT-PCR screening, COVID-19 testing with serology can delineate immune individuals at a prevalence threshold as low as 4.3%. As the

seropositive rates continue to increase, we deduce that above a prevalence of 4.3%, a positive COVID-19 IgG screen can be reliably accepted as a true positive. In contrast, the nasal RT-PCR test is most reliable when over 9.3% of the population has actively replicating virus at any given time – a value thankfully thus far not reached, even after accounting for an excess positive cases that are not tested.

Several countries have already started employing serology-based testing, either for research purposes or to grant ‘immunity certificates’ to those in whom antibodies to COVID-19 are found [6]. However, we must bear in mind that just as with RT-PCR testing, serologic testing has inherent limitations related to the lag between acute infection and the development of IgM and IgG antibodies as well. In the United States, the Centers for Disease Control and Prevention (CDC) recently released a COVID-19 Serology Surveillance Strategy [7]. This strategy aims to employ serology testing, termed ‘seroprevalence,’ at the large-scale (ie. highly impacted areas such as New York and Washington), the community-scale (with systematic selection of participants) and the small-scale (specific subgroups, eg. healthcare workers). From the reasoning above, we conclude that the best screening method to assess for acute infectivity, the need for isolation, and the ensuing social and economic repercussions, is nasal swab RT-PCR for actively replicating virus. In contrast, the most reliable screening method to assess for disease prevalence and burden of disease is antibody testing via serology – assuming enough time has lapsed since the acute infectious episode.

Note on Rapid Diagnostic Testing

In an effort to expedite testing speed and availability, rapid diagnostic tests (RDT) have been developed for point-of-care use [8-17]. These tests rely on serological markers

against SARS-CoV-2, either IgM or IgG, for diagnosis of acute COVID-19 infection. While the FDA has approved various RDTs for use under Emergency Use Authorization, the WHO currently does not recommend their use outside of research purposes due to their inconsistent sensitivities [18]. Indeed, concerns over reports of false negative results prompted an FDA news release cautioning the public about the potential inaccuracy of Abbott's ID NOW point-of-care RDT [13-17, 19]. Further studies with larger sample sizes and clear manufacturer instructions for correct sampling are needed in order to determine whether RDTs are reliable for clinical use.

Conclusion

The aforementioned values for sensitivity and specificity are likely to change as more samples are obtained. However, their values as stipulated here are used not to endorse a particular test, but to illustrate the concept of prevalence thresholds in the context of the current pandemic. To illustrate the methods herein described, we provide the example of the screening strategies used in the SARS-CoV-2 (COVID-19) pandemic, and calculate the prevalence threshold statistics of different tests available today. This concept can help contextualize the validity of a screening test in real time, thereby enhancing our understanding of the dynamics of the current pandemic. [Identifying where this prevalence point lies in the curve has important implications for the interpretation of test results, the administration of healthcare systems, the implementation of public health measures, and in cases of pandemics like SARS-CoV-2, the functioning of society at large.

Table 1. Prevalence thresholds (ϕ_e) for different serologic tests available				
Test name	Test type	Sensitivity (%)	Specificity (%)	* ϕ_e
Cellex	RDT	93.8	95.6	16.1
Autobio	RDT	95.7, 99.0	99.0	9.1
DiaSorin	ELISA	90.0-97.0	98.0	15.1
Bio-Rad	Modified ELISA	98.0	99.0	9.2
Roche	ECLIA	65.5-100.0	99.8	4.3
Euroimmun	ELISA	13.9-100.0	100.0	n/a
ChemBio	RDT	Not available	Not available	n/a
Ortho-Clinical	ELISA	Not available	Not available	n/a
Mount Sinai	ELISA	Not available	Not available	n/a
Wadsworth	Microsphere	Not available	93-100	n/a
Abbott	CMIA	Not available	Not available	n/a
*The highest sensitivity was used for calculation of prevalence thresholds for tests with a range of sensitivities. <i>CMIA</i> (chemiluminescent immunoassay); <i>ECLIA</i> (electro-chemiluminescence immunoassay); <i>ELISA</i> (enzyme-linked immunosorbent assay); <i>RDT</i> (rapid diagnostic test).				

197

198

199

200 **References**

- 201 1. *WHO Coronavirus Disease (COVID-19) Dashboard*. May 17, 2020]; Available
202 from: <https://covid19.who.int>.
- 203 2. Mizumoto, K., et al., *Estimating the asymptomatic proportion of coronavirus*
204 *disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship,*
205 *Yokohama, Japan, 2020*. Euro Surveill, 2020. **25**(10).
- 206 3. Nishiura, H., et al., *Estimation of the asymptomatic ratio of novel coronavirus*
207 *infections (COVID-19)*. Int J Infect Dis, 2020. **94**: p. 154-155.
- 208 4. *ACCELERATED EMERGENCY USE AUTHORIZATION (EUA) SUMMARY*
209 *COVID-19 RT-PCR TEST (LABORATORY CORPORATION OF AMERICA)*.
210 U.S. Food and Drug Administration. p. 1-12.
- 211 5. *Serology-based tests for COVID-19*. May 17, 2020]; Available from:
212 [https://www.centerforhealthsecurity.org/resources/COVID-19/serology/Serology-](https://www.centerforhealthsecurity.org/resources/COVID-19/serology/Serology-based-tests-for-COVID-19.html)
213 [based-tests-for-COVID-19.html](https://www.centerforhealthsecurity.org/resources/COVID-19/serology/Serology-based-tests-for-COVID-19.html).
- 214 6. Gigi Gronvall, N.C., Amanda Kobokovich, Rachel West, Kelsey Lane Warmbrod,
215 Matthew P Shearer, Lucia Mullen, Tom Inglesby, *Developing a National Strategy*
216 *for Serology (Antibody Testing) in the United States*. The Johns Hopkins Center
217 for Health Security. p. 1-38.
- 218 7. *COVID-19 Serology Surveillance Strategy*. May 17, 2020]; Available from:
219 [https://www.cdc.gov/coronavirus/2019-ncov/covid-data/serology-](https://www.cdc.gov/coronavirus/2019-ncov/covid-data/serology-surveillance/index.html)
220 [surveillance/index.html](https://www.cdc.gov/coronavirus/2019-ncov/covid-data/serology-surveillance/index.html).
- 221 8. *DPP COVID-19 IgM/IgG System*. 2020, ChemBio Diagnostic Systems. p. 1-31.
- 222 9. *Cellex qSARS-CoV-2 IgG/IgM Rapid Test*. 2020. p. 1-5.

- 223 10. Pan, Y., et al., *Serological immunochromatographic approach in diagnosis with*
224 *SARS-CoV-2 infected COVID-19 patients*. J Infect, 2020.
- 225 11. Li, Z., et al., *Development and clinical application of a rapid IgM-IgG combined*
226 *antibody test for SARS-CoV-2 infection diagnosis*. J Med Virol, 2020.
- 227 12. Cassaniti, I., et al., *Performance of VivaDiag COVID-19 IgM/IgG Rapid Test is*
228 *inadequate for diagnosis of COVID-19 in acute patients referring to emergency*
229 *room department*. J Med Virol, 2020.
- 230 13. Zhen, W., et al., *Clinical Evaluation of Three Sample-To-Answer Platforms for*
231 *the Detection of SARS-CoV-2*. J Clin Microbiol, 2020.
- 232 14. Smithgall, M.C., et al., *Comparison of Cepheid Xpert Xpress and Abbott ID Now*
233 *to Roche cobas for the Rapid Detection of SARS-CoV-2*. J Clin Virol, 2020: p.
234 104428.
- 235 15. Rhoads, D.D., et al., *Comparison of Abbott ID Now, Diasorin Simplexa, and CDC*
236 *FDA EUA methods for the detection of SARS-CoV-2 from nasopharyngeal and*
237 *nasal swabs from individuals diagnosed with COVID-19*. J Clin Microbiol, 2020.
- 238 16. Harrington, A., et al., *Comparison of Abbott ID Now and Abbott m2000 methods*
239 *for the detection of SARS-CoV-2 from nasopharyngeal and nasal swabs from*
240 *symptomatic patients*. J Clin Microbiol, 2020.
- 241 17. Basu, A., et al., *Performance of the rapid Nucleic Acid Amplification by Abbott*
242 *ID NOW COVID-19 in nasopharyngeal swabs transported in viral media and dry*
243 *nasal swabs, in a New York City academic institution*. bioRxiv, 2020: p. 1-19.
- 244 18. *Advice on the use of point-of-care immunodiagnostic tests for COVID-19:*
245 *Scientific brief*. World Health Organization. p. 1-2.

- 246 19. *Coronavirus (COVID-19) Update: FDA Informs Public About Possible Accuracy*
247 *Concerns with Abbott ID NOW Point-of-Care Test*. 2020, U.S. Food and Drug
248 Administration.
249